Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02251483 · ClinicalTrials.gov registry record · NA
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
A NA study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02251483: Completed NA study, sponsored by Cedars-Sinai Medical Center.
NCT02251483 is a NA study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02251483, a NA study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful treatment with rifaximin can lead to more prolonged duration of benefit and delay symptom recurrence. SBI is the main ingredient in EnteraGam™, an orally administered prescription medical food for the dietary management of patients with enteropathy or chronic loose or frequent stools, including patients with IBS-D.
Interventions
- OTHER Placebo
- OTHER Serum-derived bovine immunoglobulin protein isolate (SBI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-07 |
| Phase | NA |
What the finished NCT02251483 record still lists
NCT02251483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02251483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02251483 about?
NCT02251483 is a clinical study titled "Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth". The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful treatment with rifaximin can lead to more prolonged duration of benefit and...
What is the current status of trial NCT02251483?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2014-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02251483?
The interventions under investigation include: Placebo (OTHER), Serum-derived bovine immunoglobulin protein isolate (SBI) (OTHER).
Who is sponsoring clinical trial NCT02251483?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02251483's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia